Literature DB >> 25838403

Response to "clinical relevance of CYP3A5 genotype on maraviroc exposures".

Yanhui Lu1, Edward J Fuchs1, Craig W Hendrix1, Namandjé N Bumpus2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25838403      PMCID： PMC4407709          DOI： 10.1124/dmd.115.064188

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN： 0090-9556            Impact factor:   3.922


× No keyword cloud information.
  4 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Clinical relevance of CYP3A5 genotype on maraviroc exposures.

Authors:  Manoli Vourvahis; Lynn McFadyen; Jayvant Heera; Andrew Clark
Journal:  Drug Metab Dispos       Date:  2015-05       Impact factor: 3.922

Review 3.  Genetic contribution to variable human CYP3A-mediated metabolism.

Authors:  Jatinder K Lamba; Yvonne S Lin; Erin G Schuetz; Kenneth E Thummel
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

4.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.

Authors:  Yvonne S Lin; Amy L S Dowling; Sean D Quigley; Federico M Farin; Jiong Zhang; Jatinder Lamba; Erin G Schuetz; Kenneth E Thummel
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436
  4 in total
  1 in total

Review 1.  The dawn of precision medicine in HIV: state of the art of pharmacotherapy.

Authors:  Ying Mu; Sunitha Kodidela; Yujie Wang; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Pharmacother       Date:  2018-09-20       Impact factor: 3.889
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.